| Symbol | WHWK |
|---|---|
| Name | WHITEHAWK THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2 HEADQUARTERS PLAZA EAST BUILDING,11TH FLOOR, MORRISTOWN, New Jersey, 90272, United States |
| Telephone | +1 (551) 321-2234 |
| Fax | — |
| — | |
| Website | https://www.whitehawktx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001422142 |
| Description | Whitehawk Therapeutics is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawks advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Whitehawk Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000947871-26-000805 <b>Size:</b> 17 KB
Read moreNew Form SCHEDULE 13G/A - Whitehawk Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001493152-26-038432 <b>Size:</b> 25 KB
Read moreWhitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Read moreDalal Anupam 🟢 acquired 1.3M shares (1 derivative) of Whitehawk Therapeutics, Inc. (WHWK) at $4.16 ($5.2M) Transaction Date: May 14, 2026 | Filing ID: 000004
Read moreZhao Baiteng 🟢 acquired 38.0K shares (1 derivative) of Whitehawk Therapeutics, Inc. (WHWK) at $4.16 Transaction Date: Jun 12, 2026 | Filing ID: 000003
Read moreReeve Emma 🟢 acquired 38.0K shares (1 derivative) of Whitehawk Therapeutics, Inc. (WHWK) at $4.16 Transaction Date: Jun 12, 2026 | Filing ID: 000005
Read moreMaroun Richard E 🟢 acquired 38.0K shares (1 derivative) of Whitehawk Therapeutics, Inc. (WHWK) at $4.16 Transaction Date: Jun 12, 2026 | Filing ID: 000003
Read moreDesai Neil 🟢 acquired 38.0K shares (1 derivative) of Whitehawk Therapeutics, Inc. (WHWK) at $4.16 Transaction Date: Jun 12, 2026 | Filing ID: 000003
Read moreCastelein Caley 🟢 acquired 38.0K shares (1 derivative) of Whitehawk Therapeutics, Inc. (WHWK) at $4.16 Transaction Date: Jun 12, 2026 | Filing ID: 000007
Read moreAghazadeh Behzad 🟢 acquired 38.0K shares (1 derivative) of Whitehawk Therapeutics, Inc. (WHWK) at $4.16 Transaction Date: Jun 12, 2026 | Filing ID: 000006
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07470853 | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With … | Phase1 | PROC | Recruiting | 2026-03-15 | 2028-02-01 | ClinicalTrials.gov |
| NCT07444814 | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody D… | Phase1 | Endometrial Cancer | Recruiting | 2025-12-19 | 2028-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Bevacizumab | Other | Phase PHASE1 | PROC | RECRUITING | NCT07470853 |
| HWK-016, MUCIN-16-targeted ADC | Other | Phase PHASE1 | PROC | RECRUITING | NCT07470853 |
| Bevacizumab | Other | Phase PHASE1 | PROC | RECRUITING | NCT07470853 |
| HWK-016, MUCIN-16-targeted ADC | Other | Phase PHASE1 | PROC | RECRUITING | NCT07470853 |
| HWK-007 | Other | Phase PHASE1 | Endometrial Cancer | RECRUITING | NCT07444814 |
| Bevacizumab | Other | Phase PHASE1 | PROC | RECRUITING | NCT07470853 |
| HWK-016, MUCIN-16-targeted ADC | Other | Phase PHASE1 | PROC | RECRUITING | NCT07470853 |
| HWK-007 | Other | Phase PHASE1 | Endometrial Cancer | RECRUITING | NCT07444814 |
| Bevacizumab | DRUG | Phase PHASE1 | PROC | RECRUITING | NCT07470853 |
| HWK-016, MUCIN-16-targeted ADC | DRUG | Phase PHASE1 | PROC | RECRUITING | NCT07470853 |
| HWK-007 | DRUG | Phase PHASE1 | Endometrial Cancer | RECRUITING | NCT07444814 |